Stilboestrol pretreatment of children with short stature does not affect the growth hormone response to growth hormone-releasing hormone.
Oestrogens are known to enhance both basal and stimulated GH secretion. To examine whether this effect is mediated through the hypothalamus or the pituitary we performed insulin tolerance and GH-releasing hormone (GHRH) tests with and without oestrogen priming in a group of 14 short children. Pretreatment with stilboestrol increased basal levels of GH and both peak and incremental levels during insulin hypoglycaemia. In contrast, there was no effect of stilboestrol priming on the GH response to either an i.v. bolus of 100 micrograms or 0.1 microgram/kg (range 2-6 microgram) of GHRH. The children had significantly higher GH responses to an unprimed GHRH than unprimed insulin tolerance test. We conclude stilboestrol priming acts through the hypothalamus presumably by increasing endogenous GHRH release, and that short children with a subnormal GH response to insulin hypoglycaemia show a greater response to GHRH; this suggests the presence of a hypothalamic cause for their decreased GH secretion.
D001827:Body Height; D002648:Child; D002675:Child, Preschool; D004054:Diethylstilbestrol / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007003:Hypoglycemia / Q000097:blood; D007031:Hypothalamus / Q000187:drug effects; D007328:Insulin / Q000494:pharmacology
D007328:Insulin; D004054:Diethylstilbestrol; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone